Additionally, GLP-1 inhibits the release of a hormone called glucagon from the pancreas, which reduces the liver's production of glucose
Lab-tested and sterile Long shelf life Safe for peptide and chemical reconstitution Packaged with care for reliable delivery
According to the International Diabetes Federation (IDF), 589 million adults (20-79 years) are living with diabetes, and in 2024, statistics show that diabetes alone caused 3.4 million deaths
Cipla and Biocon Limited are similarly advancing semaglutide programs, with Biocon's experience in biosimilar biologics production providing relevant technical capabilities applicable to the biotechnological API production route
Supports GLP-1 naturally* Formulated with: Akkermansia muciniphila generates the postbiotics propionate and p9 which supports GLP-1 production* Clostridium butyricum produces the postbiotic butyrate which stimulates GLP-1.* Bifidobacterium infantis produces the postbiotics acetate and lactate which feed bacteria such as Akkermansia and Butyricum, promoting an ecosystem in the gut that supports a healthy gut lining and GLP-1 naturally.* Refrigerate upon arrival
Additionally, 67% of participants treated with GSBR-1290 achieved at least a 6% reduction in weight within the 12-week study period
.png)
